U.S. Food and Drug Administration · Publisher of the Depo-Provera CI prescribing information
Finding: The December 2025 label says meningiomas have been reported after repeated doses, mostly with long-term use, and tells doctors to stop the drug if a meningioma is diagnosed.
FDA: Depo-Provera CI prescribing information (revised December 2025) (opens in a new tab) · Dec 12, 2025 · Checked Oct 5, 2026